Skip to content

Nasal Septum Autologous Chondrocytes Transplantation for Condylar Resorption After Orthognathic Surgery

Clinical Study for the Evaluation of the Safety and Effectiveness of Autologous Chondrocytes Transplantation for the Treatment of Condylar Resorption Associated With Dentofacial Deformities

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03137914
Enrollment
10
Registered
2017-05-03
Start date
2015-05-08
Completion date
2020-12-02
Last updated
2021-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Temporomandibular Joint Disorders

Keywords

orthognathic surgery, TMJ, osteoarthritis

Brief summary

This clinical study has as main objective to evaluate if the Nasal Septum Autologous Chondrocytes Transplantation for Condylar Resorption is safe and effective in the treatment of degenerative lesions of temporomandibular joint (TMJ). It is a case series, in which 10 participants with diagnosis of condylar reabsorption of TMJ will be selected, with orthognathic surgery indicated. Orthognathic surgery is conventionally indicated for patients with condylar resorption to correct dentofacial deformity and, therefore, will not be performed only in function of this clinical study. The selected participants will be submitted to nasal cartilage biopsy, for isolation and preparation of the chondrocytes. The only experimental group to be evaluated will be the group treated with autologous chondrocytes diluted in hyaluronic acid. The experimental treatment will be performed 15 days after orthognathic surgery, and will be injected through arthrocentesis. Clinical follow- up will be performed in the following periods: 7 and 15 days and 1, 3, 6 and 12 months after treatment. During the consultations, participants will also be evaluated for the intensity and severity of the pain experienced, as well as the disability related to it, through the same system used for the diagnostic classification (RDC / TMD). Imaging of the TMJ will be performed before, 6 and 12 months after the injection of the experimental treatment for bone and cartilaginous joint tissue analysis. Autologous chondrocyte implantation is expected to promote the regeneration of TMJ cartilage tissue safely and effectively.

Detailed description

The only experimental group to be evaluated will be the group treated with autologous chondrocytes diluted in hyaluronic acid, to be included in groups of 2, 4 and 4 participants. Only two participants will initially be included. If these two treated participants do not present adverse effects in 3 months, we will start a second stage with 4 participants. Again we will analyze the group over 3 months and if there are no problems we will include the 4 final participants, totaling the 10 participants.

Interventions

BIOLOGICALAutologous chondrocyte transplantation

intraarticular injection into the TMJ (arthrocentesis) of autologous chondrocytes diluted in hyaluronic acid

PROCEDUREorthognathic surgery

Orthognathic surgery for correction of dentofacial deformity, performed before the cellular transplantation

Sponsors

Faculdade de Medicina de Petrópolis Faculdade Arthur Sá Earp Neto
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Single Group Assignment The clinical study model adopted is a single experimental group. Ten participants with dentofacial deformities related to severe degenerative TMJ changes, who are candidates for orthognathic surgery to repair these deformities, will be evaluated, who will be submitted to treatment with nasal septum autologous chondrocytes transplantation. There will be no evaluation of the control group in this study, as it is a case report. Injection of the experimental treatment will be done through an ultrasound-guided arthrocentesis.

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

1. Clinical diagnosis of dentofacial deformities related to osteoarthritis of TMJ; 2. must have surgical indication.

Exclusion criteria

1. pregnant or breastfeeding; 2. infection or other comorbidities; 3. rheumatologic diseases; 4. chronic pain in another joint; 5. chronic use of corticosteroids and immunosuppressants.

Design outcomes

Primary

MeasureTime frameDescription
Clinical improvement of the research participant after cell transplantation over 12 monthsThe clinical evaluations will be performed 7 and 15 days and 1, 3, 6 and 12 months after a treatment applicationThe function of the temporomadibular joint will be evaluated through the system used for the diagnostic classification Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD).

Secondary

MeasureTime frameDescription
Regeneration of articular cartilage after cellular transplantationThe imaging tests (by computed tomography) will be performed 6 and 12 months after the cellular transplantationThe participant will be submitted to the image examination (computed tomography) for evaluation of the articular osteochondral tissue.
Improvement of the researcher's quality of life after cell transplantation over 12 monthsThe questionnaires will be applied will be performed 7 and 15 days and 1, 3, 6 and 12 monthsThe participants will be evaluated according to the questionnaire Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) to evaluate satisfaction with experimental treatment.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026